Zena Burgess

MindBio Therapeutics Pty Ltd. is a multi-award-winning leader in microdosing psychedelic medicines. The company is based in Melbourne, Australia, and has subsidiaries in Australia. MindBio Therapeutics is focused on creating treatments for mental health conditions, and its clinical trials focusing on microdosing psychedelic medicines provide hope for sufferers of mental health conditions. The Australian company has conducted a randomized, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males. MindBio Therapeutics was founded by Justin Adam Hanka, and the CEO is Colin Keating.

The Australian Patients Association Ltd. is an independent not-for-profit organization that advocates for positive patient improvement and champions the rights and interests of patients in Australia. The Australian Patients Association is based in Melbourne, Australia, and Stephen Leslie Mason has been the CEO of the company since 2011. The association influences the development of national healthcare policy and reform to improve patient care and health outcomes for all Australians. The Australian company provides patient advocacy, information, and support, and offer special benefits to their members. The association values the input of patients and conducts surveys to understand their concerns and needs.